drug discoverybriefings.

A laboratory bench with a glowing data trail connecting scientific instruments to a server rack, symbolizing agentic AI embedded in drug discovery.

When the Scientist Is an Agent: Governing AI Before It Reaches the IND

Ono Pharmaceutical's rollout of agentic AI to every discovery scientist exposes a governance gap that sits upstream of any device or wearable regulation.

Abstract layered glass and molecular lattice imagery symbolizing two different speeds within a regulated system

AI Drug Discovery's Capital Boom Sits Outside the Regulatory Perimeter, Not Ahead of It

Discovery-stage AI funding is surging, but the mismatch compliance leaders should track is structural, not a simple case of regulation lagging money.

Abstract image of glowing molecular data threads converging into an automated laboratory arm.

The Traceability Debt Building Inside AI-Native Drug Discovery

Closed-loop AI discovery platforms are compressing timelines faster than biopharma governance functions can build the audit trail regulators will eventually demand.

Glowing light trails inside translucent glass panels converge down a laboratory corridor, symbolizing scattered data provenance consolidating toward a single verifiable record.

The Documentation Debt AI Drug Discovery Keeps Repeating

AI drug discovery's funding-to-approval gap echoes a governance failure regulators have already documented in medical devices, and the fix is the same.

Glowing molecular structures hover above empty hospital gurneys in a dim laboratory, symbolizing the gap between AI-driven discovery and clinical trial execution.

The AI Drug Discovery Boom Is Outrunning Trial Execution

Generative AI is accelerating molecule design, but no AI-discovered drug has cleared trials, and regulators have yet to define how AI governs the trials themselves.

Molecular structures blending into a tangled network of glowing nodes, symbolizing the shift from complicated to complex AI systems in drug discovery.

Complicated Is Not Complex: The Governance Gap in AI Drug Discovery

Drug discovery leaders are validating AI systems as if they were complicated, when the real risk is that they behave as complex, emergent systems.

A crystalline quantum lattice merging into a glowing DNA helix, symbolizing quantum-enhanced AI drug discovery

Quantum-Classical AI Enters Drug Discovery, Validation Frameworks Don't

Quantum-enhanced generative AI is moving into drug discovery pipelines faster than GxP validation and data integrity practices can absorb it.

A droplet frozen mid-fall above a rippling pool, symbolizing a preserved moment of model state before it changes.

Your AI Contract Needs a Retention Clause, Not an Ownership Clause

Locked versus adaptive AI is a settled regulatory distinction. The unsettled question is whether contracts require anyone to preserve the model state behind a licensed output.